Safety and immunogenicity of live attenuated human-bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1, 2, 3 or 4 in adults, children and infants

Mary Lou Clements-Mann, Mamodikoe K. Makhene, Jacek Mrukowicz, Peter F. Wright, Yasutaka Hoshino, Karen Midthun, Ellen Sperber, Ruth Karron, Albert Z. Kapikian

Research output: Contribution to journalArticle

Abstract

Live rotavirus vaccine candidates representing VP7 serotypes 1, 2, 3 or 4 derived by reassortment between bovine UK rotavirus and human rotavirus strains D, DS-1, P or ST3 were evaluated for safety and immunogenicity in adults, children and infants. Infection was defined by evidence of rotavirus shed in stools or a 4-fold or greater increase in serum rotavirus-specific IgA or IgG ELISA or plaque reduction neutralization antibody. A single oral dose (105.3 or 105.8 pfu) of reassortant virus was well tolerated and infected most infants: 10/20 (50%) by D x UK; 9/11 (82%) by DS-1 x UK; 8/10 (80%) by P x UK and 13/14 (93%) by ST3 x UK. All 14 infants given two doses of D x UK were infected. These findings demonstrating satisfactory levels of attenuation, safety, infectivity and immunogenicity of each reassortant in infants warrant additional studies of a candidate vaccine containing these four strains.

Original languageEnglish (US)
Pages (from-to)2715-2725
Number of pages11
JournalVaccine
Volume17
Issue number20-21
DOIs
StatePublished - Jun 4 1999

    Fingerprint

Keywords

  • Diarrheal vaccines
  • Human-bovine reassortant rotavirus vaccines
  • Live attenuated virus vaccines
  • Pediatric vaccines
  • Rotavirus vaccines

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Clements-Mann, M. L., Makhene, M. K., Mrukowicz, J., Wright, P. F., Hoshino, Y., Midthun, K., Sperber, E., Karron, R., & Kapikian, A. Z. (1999). Safety and immunogenicity of live attenuated human-bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1, 2, 3 or 4 in adults, children and infants. Vaccine, 17(20-21), 2715-2725. https://doi.org/10.1016/S0264-410X(98)00497-6